Aion Therapeutic Provides Notice of Default

Aion Therapeutic Inc. (CSE: AION) (" Aion Therapeutic " or the " Company ") announces that it anticipates being late in filing its audited annual financial statements (the " Annual Financial Statements ") and related management discussion and analysis (" MD&A ") for the year ended April 30, 2021 by the prescribed deadline of August 30, 2021 and its interim financial statements (the " Interim Financial Statements ") and related MD&A for the interim period ended July 31, 2021 by the prescribed deadline of September 29, 2021 .

Aion Therapeutic Inc. Logo (CNW Group/Aion Therapeutic Inc.)

During the year ended April 30, 2021 , the Company completed the acquisition of 1196691 B .C. Ltd. d/b/a PCAI Pharma. As a result of this acquisition, the Company is delayed in providing its independent auditors with the necessary valuations and impairment testing required to gain reasonable comfort to complete and file the Annual Financial Statements and MD&A.

The Company has made an application with the applicable securities regulators under National Policy 12-203 – Cease Trade Orders for Continuous Disclosure Defaults (" NP 12-203 ") requesting that a management cease trade order be imposed in respect of the anticipated late filing rather than an issuer cease trade order. The issuance of a management cease trade order does not affect the ability of persons who have not been directors, officers or insiders of the Company to trade in their securities.

The Company anticipates that it will in a position to prepare and file the Annual Financial Statements and related MD&A on or prior to September 29, 2021 , and prepare and file the Interim Financial Statements and related MD&A on or prior to October 29, 2021 .

The Company confirms that it will satisfy the provisions of the alternative information guidelines under NP 12-203 by issuing bi-weekly default status reports in the form of news releases for so long as it remains in default of the filing requirements to file the Financial Statements, the Interim Financial Statements and related MD&A within the prescribed period of time. The Company confirms that there is no other material information relating to its affairs that has not been generally disclosed.

About Aion Therapeutic Inc.

Aion Therapeutic Inc. through its wholly-owned subsidiary, AI Pharmaceuticals Jamaica Limited, is in the business of research and development, treatment, data mining and state-of-the-art artificial intelligence (machine learning) techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi (edible mushroom), natural psychedelic formulations (Ayahuasca), and other medicinal plants in a legal environment for this type of discovery. In addition, Aion Therapeutic is creating a strong international intellectual property portfolio related to its discoveries.

DISCLAIMER & READER ADVISORY

Certain information set forth in this news release may contain forward-looking information that involve substantial known and unknown risks and uncertainties. This forward-looking information is subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to, the impact of general economic conditions, industry conditions, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking information. The parties undertake no obligation to update forward-looking information except as otherwise may be required by applicable securities law.

SOURCE Aion Therapeutic Inc.

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/August2021/31/c1920.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)

U.S. Cannabis Market Soars Amid Legal Reforms, But Safety Concerns Persist

-

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Trulieve Announces Opening of Affiliated Medical Marijuana Dispensary in Wilkes-Barre, Pennsylvania

New dispensary expands patient access to medical marijuana with ribbon cutting and pop-up event

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing marijuana company in the U.S., today announced the opening of a new Trulieve-affiliated medical marijuana dispensary in Wilkes-Barre, Pennsylvania .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve to Open Medical Cannabis Dispensary in Gulf Breeze, Florida

New Santa Rosa County location will host grand opening celebration Friday, July 12th

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the opening of a new medical cannabis dispensary in Gulf Breeze, Florida .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Cannabis Corp. to Hold Second Quarter 2024 Results Conference Call on August 6, 2024

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., will hold a conference call on Tuesday, August 6, 2024 at 8:30 AM Eastern Time following the release of its second quarter 2024 financial results.

Trulieve logo (PRNewsfoto/Trulieve Cannabis Corp.)

Chairman, Founder, and Chief Executive Officer Kim Rivers and Chief Financial Officer Wes Getman will participate on the call to review Trulieve's financial and operating results.

Interested parties can join the conference call by dialing in as directed below. Please dial in 15 minutes prior to the call and ask to join the Trulieve Cannabis Corp. call.

North American toll free: 1-844-824-3830

Passcode:

1732811

International: 1-412-542-4136

Passcode:

1732811

A live audio webcast of the conference call will be available at:
Trulieve Second Quarter 2024 Results Call

An archived replay of the webcast will be available at:
https://investors.trulieve.com/events

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .

Facebook: @Trulieve
Instagram: @Trulieve _
X: @Trulieve

Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-cannabis-corp-to-hold-second-quarter-2024-results-conference-call-on-august-6-2024-302191314.html

SOURCE Trulieve Cannabis Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2024/09/c4702.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Hygrovest Limited

HGV Appendix 4D - Half Year Report

Hygrovest Limited (ASX:HGV) ("HGV")is an Australian-listed specialist investment company which concentrates on producing capital growth for shareholders over the medium to long term from investments in listed and unlisted equities and other financial assets.

HGV encloses the Appendix 4D and financial statements in respect of the half year ended 31 December 2021 lodged in accordance with ASX LR4.2B.

Keep reading...Show less

Cronos Group Inc. to Reconvene Virtual 2024 Annual Meeting of Shareholders

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") announced today that it will reconvene its 2024 Annual Meeting of Shareholders on Friday, July 19, 2024, at 11:00 a.m. ET.

Cronos will be conducting the reconvened meeting in a virtual-only format via live audio webcast. Registered shareholders and duly appointed proxyholders will have an equal opportunity to participate in the reconvened 2024 Annual Meeting online regardless of their geographic location, including a chance to ask questions and vote.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×